Hormonal
Dietary weight loss via a hypocaloric DASH-based diet significantly reduces sympathetic nervous system (SNS) activity (norepinephrine spillover and muscle sympathetic nerve activity) and improves cardiac baroreflex sensitivity in subjects with metabolic syndrome.
For individuals with metabolic syndrome, a structured weight loss program using a modified DASH diet (moderate fat, higher protein, low sodium) for 12 weeks can significantly reduce harmful sympathetic nervous system activity and improve heart health markers. This approach targets the root metabolic drivers (insulin resistance and leptin levels) rather than just weight, offering cardiovascular protection beyond simple fat loss.
Weight loss by a hypocaloric diet with moderate sodium restriction diminishes SNS activity in MetS subjects. This may be due to the consequences of decreased leptin concentration, enhanced insulin sensitivity, or improvements in cardiac baroreflex function.
Why this rating
Single-sample, repeated measures design with objective physiological measures (microneurography, isotope dilution), but lacks a control group.
Source
Effects of Dietary Weight Loss on Sympathetic Activity and Cardiac Risk Factors Associated with the Metabolic Syndrome
Nora E. Straznicky et al. · The Journal of Clinical Endocrinology & Metabolism · 2005
DOI 10.1210/jc.2005-0961
More from this paper
- The reduction in sympathetic activity (norepinephrine spillover) following weight loss is independently associated with the reduction in plasma leptin concentrations, suggesting leptin mediates this effect.Good
- Insulin-resistant subjects experience a significant reduction in whole-body norepinephrine spillover after weight loss, whereas insulin-sensitive subjects do not, despite similar weight loss amounts.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →